Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
In the landmark STEP 1 trial, adults with obesity lost an average of 14.9% of their body weight over 68 weeks, versus 2.4% on placebo (New England Journal of Medicine, 2021)
The Future of GLP-1 Medications As demand for GLP-1 receptor agonists continues to grow, questions remain about their role in healthcare
GHK-Cu Regulatory Status GHK-Cu occupies a unique dual-category position in US regulation: Cosmetic-grade GHK-Cu permitted as a cosmetic ingredient in skincare products at controlled concentrations Research-grade GHK-Cu sold under research-use-only labeling for in-vitro and animal research Not FDA-approved as a drug no pharmaceutical approval for systemic therapeutic use Not WADA-prohibited unlike some peptides, GHK-Cu is not on the WADA Prohibited List as of current updates Not DEA-scheduled no controlled substance status For the complete legal framework around research peptides, see our detailed guide on are peptides illegal
Perhaps unsurprisingly, there is a strong correlation with body mass index (BMI)
US$ 29.77
US$ 26.12
US$ 28.55
US$ 23.29
US$ 29.90
